TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07284186: First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Sponsor: Plexium, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 155 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$7,162,848

Rescue Site Savings

+$4,712,400

Unlock Full NCT07284186 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07284186 Rescue Dossier →